Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Thistle and Reduced Hepatic Steatosis

Doses used in studies

mg/day: 103.2 (median 103.2, IQR 103.2–103.2) — 1 study

Time to effect

Median: 5.6 months · IQR 5.6 months–5.6 months · Range 5.6 months–5.6 months — Reported in 1 of 2 studies

2 of 2 papersPopulation:

Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.
- 2024-08-03
- RCT · n = 83
- Lipids in health and disease 23(1)
- - Yufeng Jin
  - Xin Wang
  - Ke Chen
  - Yu Chen
  - Lixin Zhou
  - Yupeng Zeng
  - Yuqing Zhou
  - Zhijun Pan
  - Di Wang
  - Zhongxia Li
  - Yongqian Liang
  - Wenhua Ling
  - Dan Li
- PubMed: 39097726
- DOI: 10.1186/s12944-024-02220-y
19 Insights on
- Reduced Hepatic Steatosis
- High evidence
- Clinical
but had no significant effect on the controlled attenuation parameter (CAP)
Effect
Neutral
Effect size
Small
Significant
No
Dose
103.2 mg/d
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies.
- 2024-03-19
- Review
- Frontiers in nutrition 11
- - Khamis Al Hashmi
  - Rosaria Vincenza Giglio
  - Anca Pantea Stoian
  - Angelo Maria Patti
  - Khalid Al Waili
  - Khalid Al Rasadi
  - Marcello Ciaccio
  - Manfredi Rizzo
- PubMed: 38567250
- DOI: 10.3389/fnut.2024.1355732
1 Insight on
- Reduced Hepatic Steatosis
- Low evidence
Several evidences are supporting the use of silymarin, berberine, curcumin, Nigella sativa, Ascophyllum nodosum, and Fucus vesiculosus, vitamin E, coenzyme Q10 and Omega-3.
Effect
Beneficial
Effect size
Small
Significant
Yes